Projects per year
Personal profile
Research interests
To understand how the vascular complications of diabetes develop and progress and how we can target specific pathways to delay, stop or reverse diabetic micro-and macrovascular complications including heart and kidney disease.
Keywords
- Diabetes
- Diabetic complications
- diabetic nephropathy
- cardiovascular disease
- oxidative stress
- reactive oxygen species
- unstable plaque
- novel targets
- clinical translation
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2014 2022
Targeting Nox5 to prevent atherosclerosis and aneurysm formation
Jandeleit-Dahm, K. & Touyz, R. M.
1/01/19 → 31/12/22
Project: Research
Lipoxins protect against diabetes associated atherosclerosis
Jandeleit-Dahm, K., Kantharidis, P. & Godson, C.
1/01/19 → 31/12/22
Project: Research
Targeting epigenetic pathways that lead to diabetic complications
Cooper, M. E., El-Osta, A., Jandeleit-Dahm, K. & Quaggin, S.
1/01/18 → 31/12/21
Project: Research
RAGE and ACE2 shedding as therapeutic targets in diabetes and cardiovascular disease
Thomas, M. C., Jandeleit-Dahm, K., Wilton, S. D. & Tikellis, C.
1/01/17 → 31/12/19
Project: Research
Research Output 1991 2018
Lipoxins regulate the early growth response-1 network and reverse diabetic kidney disease
Brennan, E. P., Mohan, M., McClelland, A., Tikellis, C., Ziemann, M., Kaspi, A., Gray, S. P., Pickering, R., Tan, S. M., Tasadaque Ali-Shah, S., Guiry, P. J., El-Osta, A., Jandeleit-Dahm, K., Cooper, M. E., Godson, C. & Kantharidis, P., 1 May 2018, In : Journal of the American Society of Nephrology. 29, 5, p. 1437-1448 12 p.Research output: Contribution to journal › Article › Research › peer-review
Metabolic karma-the atherogenic legacy of diabetes: The 2017 edwin bierman award lecture
Cooper, M. E., El-Osta, A., Allen, T. J., Watson, A. M. D., Thomas, M. C. & Jandeleit-Dahm, K., 1 May 2018, In : Diabetes. 67, 5, p. 785-790 6 p.Research output: Contribution to journal › Article › Other
SGLT-2 Inhibition: Novel Therapeutics for Reno-and Cardioprotection in Diabetes Mellitus
Gill, A., Gray, S. P., Jandeleit-Dahm, K. & Watson, A., 17 Apr 2018, (Accepted/In press) In : Current Diabetes Reviews. 9 p.Research output: Contribution to journal › Review Article › Research › peer-review
Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease
Gray, S. P., Jha, J. C., Kennedy, K., Bommel, E. V., Chew, P., Szyndralewiez, C., Touyz, R. M., Schmidt, H. H. H. W., Cooper, M. E. & Jandeleit-Dahm, K. A. M., May 2017, In : Diabetologia. 60, 5, p. 927-937 11 p.Research output: Contribution to journal › Article › Research › peer-review
GLP-1 receptor agonists: An example of the challenge for animal models to predict plaque instability/rupture and cardiovascular outcomes
Ying, Y. L., Chen, Y. C., Jandeleit-Dahm, K. & Peter, K., 1 Oct 2017, In : Atherosclerosis. 265, p. 250-252 3 p.Research output: Contribution to journal › Editorial › Other › peer-review